Balchem (BCPC) Stock Analysis & AI Equity Report

Chemicals - Specialty USD Explore free reports

Balchem (BCPC) overview

Balchem (BCPC) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 1,037m and operating profit of USD 209m; the year-end share price was 153.36 USD and market capitalisation was USD 4,916m. Balchem is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Balchem's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 1,257mFY 2025
Share price153.36 USDFY 2025 year end
RevenueUSD 1,037mFY 2025
Operating profitUSD 209mFY 2025
Net earningsUSD 155mFY 2025
Market capitalisationUSD 4,916mFY 2025 year end

About Balchem

Balchem develops, manufactures, distributes, and markets specialty ingredients and products for nutrition, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets. Its human nutrition offerings include choline nutrients, mineral chelates, vitamin K2, and nutritional ingredients, alongside product development and microencapsulation solutions for food and beverage makers. Animal nutrition products include choline chloride, microencapsulated supplements, and chelated nutrients for livestock and companion animals.

Generate the Balchem report

Balchem is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Balchem and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Balchem

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.